Loading stock data…
Edgewise Therapeutics, Inc. (EWTX)
$40.84+1.55 (+3.95%)
Market ClosedLast close Jul 24
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Edgewise Therapeutics, Inc. in the Healthcare sector is trading at $40.84 with a market capitalization of $3.7B. Wall Street consensus targets $49.92 (13 analysts), implying a +22.2% move over the next 12 months. The stock is currently 16% below its 52-week high of $48.40, remaining 40.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +22.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$54.12M↑ | -$55.98M↓ | -$46.86M↓ | -$42.61M↑ | -$45.96M |
| Net Income | -$49.01M↑ | -$50.22M↓ | -$40.67M↓ | -$36.12M↑ | -$40.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clini...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.69%
Volume
Today's trading volume
996,421
Recent News
Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified?
How Edgewise Therapeutics Stock Has Been Trading Recently Edgewise Therapeutics (EWTX) has drawn investor attention after a period of mixed short term trading, with the stock down 2.4% over the past day but higher over the past month and past 3 months. Shares last closed at US$38.81, with the company’s total return up about 63% year to date and a much larger gain over the past year. These figures prompt closer scrutiny of what is currently priced into the stock. See our latest analysis for...
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?
VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans.
Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive
Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?
Is EWTX a good stock to buy? We came across a bullish thesis on Edgewise Therapeutics, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on EWTX. Edgewise Therapeutics, Inc.’s share was trading at $38.83 as of June 23rd. Edgewise Therapeutics is positioned as a high-conviction clinical-stage biotech transitioning into a substantially […]
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is among the best healthcare stocks. TheFly reported on June 17 that RBC Capital increased its price target for EWTX to $59 from $48 while maintaining an Outperform rating on the shares. The firm […]